Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Neurocrine Bioscienc
(NQ:
NBIX
)
122.54
-2.56 (-2.05%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Neurocrine Bioscienc
New Study Reveals How Classical Music Could Revolutionize Depression Care
August 12, 2024
In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of...
Via
PressReach
Exposures
Product Safety
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
April 16, 2024
From
Sentia Medical Sciences, Inc.
Via
GlobeNewswire
The 5 Stocks Most Sold By Insiders This Year
April 16, 2024
Insiders are selling these 5 stocks increased as their markets advanced, and gains may be capped. Long-term outlooks are positive for growth and share prices.
Via
MarketBeat
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
December 29, 2023
Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio.
Via
MarketBeat
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
February 14, 2023
From
Sentia Medical Sciences, Inc.
Via
GlobeNewswire
Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
January 25, 2023
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.
Via
MarketBeat
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
November 11, 2022
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.
Via
MarketBeat
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
September 29, 2022
Via
AB Newswire
Parkinson’s Disease Therapeutic Market Revenue Is Expected To Cross $8 Billion By 2027
May 05, 2021
Via
FinancialNewsMedia
Biotechs Aligning to Address Challenges for Developing Therapeutics for Billion Dollar Neurological Disorders Industry
April 22, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.